Outlook’s Ophthalmic Bevacizumab Knocked Back By FDA

US Agency Offers Multiple Reasons For CRL Over Outlook’s BLA For Lytenava

 
• By David Wallace
Eye
Outlook has been handed a CRL for its ophthalmic bevacizumab

More from Value Added Medicines

More from Products